|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-3-22
|
|
pubmed:abstractText |
Myeloid neoplasms are characterized by acquired somatic mutations and epigenetic alterations in genes that are crucial for hematopoietic differentiation and cellular proliferation and survival pathways. The heterogeneity and genetic complexity of these disorders is daunting, but the improvement in our knowledge of the pathogenetic mechanisms underlying myeloid transformation, coupled with the increasing availability of agents that target these pathways, offers unique opportunities for improved therapy. This review will focus on common mutations that are of therapeutic or prognostic importance in acute myeloid leukemia (AML) and the classic Philadelphia chromosome-negative myeloproliferative neoplasms (Ph(-) MPNs), in the context of discussing the potential for risk-adapted and targeted therapeutic approaches for these diseases.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CCAAT-Enhancer-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/CEBPA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Core Binding Factors,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/FLT3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/JAK2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Janus Kinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/MLL protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Myeloid-Lymphoid Leukemia Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-kit,
http://linkedlifedata.com/resource/pubmed/chemical/TET2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/fms-Like Tyrosine Kinase 3
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1532-8708
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
196-214
|
|
pubmed:meshHeading |
pubmed-meshheading:21421110-CCAAT-Enhancer-Binding Proteins,
pubmed-meshheading:21421110-Core Binding Factors,
pubmed-meshheading:21421110-DNA-Binding Proteins,
pubmed-meshheading:21421110-Epigenomics,
pubmed-meshheading:21421110-Genes, ras,
pubmed-meshheading:21421110-Humans,
pubmed-meshheading:21421110-Individualized Medicine,
pubmed-meshheading:21421110-Janus Kinase 2,
pubmed-meshheading:21421110-Karyotyping,
pubmed-meshheading:21421110-Leukemia, Myeloid, Acute,
pubmed-meshheading:21421110-Mutation,
pubmed-meshheading:21421110-Myeloid-Lymphoid Leukemia Protein,
pubmed-meshheading:21421110-Myeloproliferative Disorders,
pubmed-meshheading:21421110-Proto-Oncogene Proteins,
pubmed-meshheading:21421110-Proto-Oncogene Proteins c-kit,
pubmed-meshheading:21421110-fms-Like Tyrosine Kinase 3
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?
|
|
pubmed:affiliation |
Department of Medicine, The University of Chicago, Chicago, IL 60637, USA. todenike@medicine.bsd.uchicago.edu
|
|
pubmed:publicationType |
Journal Article,
Review
|
